WT1-ANTIGEN PEPTIDE CONJUGATE VACCINE

(19)

(11)

EP 2 982 681 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	07.11.2018 Bulletin 2018/45

(45)	Mention of the grant of the patent:
	22.08.2018 Bulletin 2018/34

(21)	Application number: 14775899.9

(22)	Date of filing: 28.03.2014

(51)

International Patent Classification (IPC):

C07K 7/06^(2006.01)
A61P 35/00^(2006.01)
C07K 14/00^(2006.01)

A61K 39/00^(2006.01)
C07K 7/08^(2006.01)

(86)	International application number:
	PCT/JP2014/059336

(87)	International publication number:
	WO 2014/157692 (02.10.2014 Gazette 2014/40)

(54)	WT1-ANTIGEN PEPTIDE CONJUGATE VACCINE WT1-ANTIGEN-PEPTID-KONJUGAT-VAKZIN VACCIN CONJUGUÉ DE PEPTIDE D'ANTIGÈNE WT1

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

29.03.2013 JP 2013072173
31.07.2013 JP 2013158383

(43)	Date of publication of application:
	10.02.2016 Bulletin 2016/06

(60)	Divisional application:
	18188307.5

(73)	Proprietors:
	Sumitomo Dainippon Pharma Co., Ltd. Osaka-shi Osaka 541-8524 (JP) International Institute of Cancer Immunology, Inc. Suita-shi, Osaka 564-0053 (JP)

(72)	Inventors:
	LI, Chiang Jia Cambridge Massachusetts 02141 (US) BAN, Hitoshi Osaka-shi, Osaka 554-0022 (JP) NISHIO, Yukihiro Osaka-shi, Osaka 554-0022 (JP) GOTO, Masashi Osaka-shi, Osaka 554-0022 (JP) NISHIHARA, Toshio Osaka-shi, Osaka 554-0022 (JP) TAKANASHI, Yosuke Osaka-shi, Osaka 554-0022 (JP)

(74)	Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB
	Siebertstrasse 3 81675 München 81675 München (DE)

(56)

References cited: :

EP-A2- 2 341 142
WO-A1-2004/063217
JP-A- 2002 525 099

WO-A1-00/06602
WO-A1-2008/081701
US-A1- 2006 217 297

GAIGER ALEXANDER ET AL: "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia", BLOOD, vol. 96, no. 4, 15 August 2000 (2000-08-15), pages 1480-1489, XP002761439, ISSN: 0006-4971
CHANG ET AL.: 'The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a ''molecular ruler'' mechanism' PROC. NATL. ACAD. SCI. vol. 102, no. 47, 2005, pages 17107 - 17112, XP055287741
MODUGNO ET AL.: 'MHC-Peptide Binding:Dimers of Cysteine-Containing Nonapeptides Bind with High Affinity to HLA-A2.1 Class I Molecules' JOURNAL OF IMMUNOTHERAPY vol. 20, no. 6, 1997, pages 431 - 436, XP002976492

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).